PUBLISHER: TechSci Research | PRODUCT CODE: 1692311
PUBLISHER: TechSci Research | PRODUCT CODE: 1692311
We offer 8 hour analyst time for an additional research. Please contact us for the details.
Global Tumor Treatment Equipment Market was valued at USD 14.10 billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 6.50% through 2030. Tumor treatment refers to the medical interventions and therapies aimed at diagnosing, managing, and eliminating tumors or abnormal growths in the body. Tumors can be benign (non-cancerous) or malignant (cancerous). The choice of treatment depends on the type, location, size, stage, and other characteristics of the tumor, as well as the patient's overall health and preferences. Surgical removal of the tumor is a common treatment option, particularly for localized and easily accessible tumors. In some cases, minimally invasive surgery, such as laparoscopy or robotic-assisted surgery, is used to reduce trauma and recovery time. Surgeons aim to remove the entire tumor along with a margin of healthy tissue to ensure complete removal. Tumor treatment is highly individualized, and the choice of therapy depends on factors like the type and stage of the tumor, the patient's overall health, and the treatment goals (curative, palliative, or symptom management). Treatment plans are often developed through a multidisciplinary approach involving oncologists, surgeons, radiation oncologists, and other healthcare professionals.
Market Overview | |
---|---|
Forecast Period | 2026-2030 |
Market Size 2024 | USD 14.10 Billion |
Market Size 2030 | USD 20.41 Billion |
CAGR 2025-2030 | 6.50% |
Fastest Growing Segment | Radiotherapy Equipment |
Largest Market | North America |
Key Market Drivers
Technological Advancements
Image-Guided Radiation Therapy (IGRT) allows for real-time imaging of the tumor and surrounding tissues during radiation therapy. For instance, in December 2024, AngioDynamics, Inc. announced that it had secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its NanoKnife System, designed for prostate tissue ablation. This regulatory approval marks a significant milestone, enabling the company to offer a minimally invasive treatment option for prostate conditions, further expanding its innovative medical device portfolio.
Also, in March 2024, Medtronic plc, a global leader in healthcare technology, announced it had received U.S. FDA 510(k) clearance for its OsteoCool 2.0 bone tumor ablation system. This advanced system is designed to treat painful bone metastases and benign bone tumors like osteoid osteoma, enhancing treatment options for patients. Advanced imaging techniques, such as cone-beam CT and MRI, enable precise tumor targeting, minimizing damage to healthy tissue. Intensity-Modulated Radiation Therapy (IMRT) delivers radiation with varying intensity levels, allowing for precise dose modulation. It can conform radiation beams to the shape of the tumor, sparing nearby critical organs. Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT) use highly focused radiation beams to treat small tumors or lesions with extreme precision. They are often used for brain tumors, lung tumors, and metastatic lesions in the body. Proton therapy uses protons instead of traditional X-rays for radiation treatment. Protons have precise energy deposition, sparing healthy tissue and reducing the risk of side effects. Cryoablation uses extreme cold to freeze and destroy tumor tissue. It is minimally invasive and can be used for various cancer types, including prostate and kidney cancer. Robotic-assisted surgery provides surgeons with enhanced precision and dexterity during procedures. It is commonly used in procedures like robotic-assisted prostatectomy. Targeted therapies are drugs that specifically target cancer cells or specific molecular pathways. Advancements in understanding cancer genetics have led to the development of more targeted and effective treatments.
Key Market Challenges
Cost of Treatment
Tumor treatment equipment, such as advanced radiation therapy machines, surgical robots, and imaging devices, can be expensive to acquire and maintain. These costs are often passed on to healthcare facilities and patients. Many cancer treatments involve the use of expensive pharmaceuticals, including chemotherapy drugs and targeted therapies. The cost of these drugs can be a significant portion of the overall treatment expenses. As tumor treatment equipment becomes more technologically advanced, it often comes with higher price tags. These technologies are essential for delivering effective and precise treatments. Cancer treatment often involves multiple modalities over an extended period, including surgery, radiation therapy, chemotherapy, and immunotherapy. The cumulative cost of these treatments can be substantial. Managing the side effects of cancer treatment, such as pain management, supportive care, and addressing treatment-related complications, adds to the overall cost. While personalized medicine can lead to more effective treatments, it can also be expensive due to the need for genetic testing, biomarker analysis, and customized drug regimens. The availability and adequacy of health insurance coverage can impact the financial burden on patients. Insufficient coverage may result in high out-of-pocket costs. Even with insurance, patients often face copayments, deductibles, and other out-of-pocket expenses, which can be financially challenging, especially for long-term treatments. In some regions, access to advanced tumor treatment equipment and therapies may be limited, either due to the lack of healthcare infrastructure or cost constraints. This can result in disparities in access to care.
Key Market Trends
Minimally Invasive Surgery
MIS techniques minimize damage to surrounding healthy tissues, resulting in less surgical trauma and a faster recovery for patients. Patients who undergo minimally invasive surgery often experience shorter hospital stays compared to traditional open surgery, reducing healthcare costs. Smaller incisions and reduced tissue exposure can lower the risk of postoperative infections. Advanced equipment, such as robotic surgical systems, provides surgeons with enhanced precision and dexterity during procedures, allowing for more precise tumor removal. Smaller incisions result in less scarring, which can lead to improved cosmetic outcomes and increased patient satisfaction. Robotic-assisted surgery is a subcategory of MIS that has seen significant growth. Surgical robots offer three-dimensional visualization and greater maneuverability during procedures. MIS is being used for the treatment of various tumors, including those in the prostate, kidney, liver, lung, and colon. The versatility of minimally invasive techniques is driving adoption. Advanced imaging technologies, such as laparoscopic and endoscopic ultrasound, aid in tumor localization and surgical planning during minimally invasive procedures. Minimally invasive surgery is associated with less postoperative pain and discomfort for patients, improving their overall experience. Patients undergoing MIS typically experience faster recovery times, allowing them to return to their normal activities sooner. Many patients prefer minimally invasive approaches when suitable because of the perceived benefits in terms of recovery and reduced scarring. Equipment used in minimally invasive surgery is continually evolving, incorporating features like improved visualization, instrument articulation, and haptic feedback.
In this report, the Global Tumor Treatment Equipment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Tumor Treatment Equipment Market.
Global Tumor Treatment Equipment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: